On Feb. 10, 2006, Acorda Therapeutics announced an initial public offering of 5,500,000 shares of common stock at a price of $6.00 per share.

Acorda is commercial-stage biopharmaceutical company, located in New York, dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.